CFTR Modulators Correct Protein Folding and Trafficking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis and related diseases, particularly those caused by mutations in the CFTR gene, such as cystic fibrosis transmembrane conductance regulator (CFTR) protein misfolding, fail to effectively enhance CFTR activity, leading to impaired protein folding and trafficking, resulting in respiratory and other organ dysfunctions.
Innovation Solution
Administration of specific compounds, represented by Formulas (I) and (II), which increase CFTR activity in human bronchial epithelial cells, including mutant forms like ΔF508, by enhancing protein folding and trafficking, potentially combined with CFTR potentiators and correctors like ivacaftor, VX-661, and lumacaftor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cystic fibrosis, then CFTR activity remains insufficient, but using new compounds may introduce unknown safety risks
Solution Approach 1:
The treatment approach is segmented into multiple classes of CFTR modulators (correctors, potentiators, amplifiers) that target different stages of CFTR processing and function. This segmentation allows for combination therapies that address multiple defects simultaneously while enabling dose optimization for each agent to maximize efficacy and minimize individual side effects.
Solution Approach 2:
The patent employs preliminary action by using correctors first to improve CFTR folding and trafficking to the cell membrane, followed by potentiators or amplifiers to enhance the function of the properly localized channels. This sequential approach ensures that the CFTR protein is first correctly positioned before attempting to maximize its functional activity, thereby reducing the risk of ineffective treatment.
2Reliability
If compounds of Formula (I) and (II) are administered to enhance CFTR activity, then protein folding and trafficking improve, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic mechanisms into a single compound structure by designing Formula (I) and (II) compounds that can simultaneously exhibit corrector, potentiator, and amplifier activities. This multi-functionality within a single molecular entity simplifies the treatment regimen compared to using separate agents for each mechanism, while still achieving comprehensive CFTR modulation.
Solution Approach 2:
The disclosed compounds are designed with universal applicability across multiple CFTR mutation types and classes. The molecular structures of Formula (I) and (II) are engineered to interact with conserved regions of the CFTR protein, enabling a single compound to potentially benefit patients with various mutations, thereby reducing the need for mutation-specific treatment development and simplifying clinical implementation.
3Reliability
If CFTR activity is increased to treat multiple organ dysfunctions, then therapeutic benefit improves, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target the defective CFTR protein in affected tissues while sparing normal proteins. The Formula (I) and (II) compounds are engineered to bind to specific conformational features of misfolded CFTR that are not present in wild-type CFTR or other proteins, thereby enhancing therapeutic benefit in affected organs while minimizing off-target effects in healthy tissues.
Solution Approach 2:
The disclosed compounds act as intermediaries that facilitate the proper folding and function of CFTR without directly forcing conformational changes that could disrupt other proteins. By serving as molecular chaperones and modulators, these compounds mediate the restoration of CFTR function through controlled interactions that prioritize specificity, thereby reducing the risk of off-target effects while achieving therapeutic benefit across multiple organs.
Data Source
AI summary
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).